Clinical Trials Logo

Covid19 clinical trials

View clinical trials related to Covid19.

Filter by:

NCT ID: NCT04768244 Completed - Covid19 Clinical Trials

Impact of Maternal COVID-19 Disease on Breast Milk and Infant Health

MilkCorona
Start date: April 1, 2020
Phase:
Study type: Observational

prospective multicenter study The main aim is to study the impact of maternal COVID-19 on breast milk immune, microbiological, and metabolic profile and infant growth and development

NCT ID: NCT04767477 Completed - Covid19 Clinical Trials

Telerehabilitation and Face-to-face Rehabilitation on COVID-19 Survivors

Start date: March 28, 2021
Phase: N/A
Study type: Interventional

INTRODUCTION: As this is a new disease, the short- and long-term consequences for patients with COVID-19 are still unclear. The use of sedatives, as well as prolonged rest, can lead to musculoskeletal damage, including decreased muscle strength and physical function. Thus, rehabilitation after this disease is a key component in continuing patient care. OBJECTIVE: To verify the effects of face-to-face cardiac rehabilitation and telerehabilitation on tolerance to the maximum and submaximal exercise, lung function, fatigue intensity and quality of life of COVID-19 survivors. METHODS: This is a longitudinal, intervention study. Primary outcomes will be maximum and submaximal functional capacity, intensity and impact of fatigue, while secondary outcomes will be lung function and quality of life. EXPECTED RESULTS: This work will bring important information to the scientific community and health professionals, about the best forms of intervention and its repercussions on the surviving individuals of COVID-19.

NCT ID: NCT04766983 Completed - Covid19 Clinical Trials

Incidence of VAP in Patients With Severe COVID-19

CoV-AP
Start date: February 28, 2020
Phase:
Study type: Observational

Combined retrospective and prospective cohort study to evaluate the incidence of microbiologically confirmed VAP in mechanically ventilated patients with COVID-19. In the retrospective part, microbiological data are based on bi-weekly surveillance ETA. In the prospective part, microbiological data are based on ETA and BAL performed on VAP suspicion. In the prospective part, immunological and virological analyses will be performed on biological samples (blood, respiratory tract) collected from patients at VAP diagnosis.

NCT ID: NCT04766931 Completed - Covid19 Clinical Trials

The Safety and Efficacy of FB2001 in Healthy Subjects and Patients With COVID-19 Infection

Start date: March 17, 2021
Phase: Phase 1
Study type: Interventional

This is an adaptive, Phase I/II study in 2 parts: Part 1 is to evaluate the Maximum Tolerable Dose (MTD) , tolerance, safety and pharmacokinetics of FB2001 in healthy subjects; Part 2 is to evaluate the safety, pharmacokinetics and efficacy of FB2001 in patients with moderate to severe COVID-19 disease.

NCT ID: NCT04766788 Completed - Covid19 Clinical Trials

Studying Students at Risk for COVID-19

Start date: September 3, 2020
Phase:
Study type: Observational

The goal of this longitudinal observational study is to learn about how the COVID-19 has impacted and continues to impact students at the University of Michigan. We hope to determine whether a combination of (1) continuous heart rate obtained from wearable devices, (2) self-reported data from surveys and symptom logs, and (3) saliva samples can be used to help students self-monitor for infection and eventually be able to create a predictive model to detect illness early.

NCT ID: NCT04766333 Completed - Covid19 Clinical Trials

New Jersey Healthcare Essential Worker Outreach and Education Study - Testing Overlooked Occupations

Start date: May 3, 2021
Phase: N/A
Study type: Interventional

This mixed methods study evaluates the effectiveness and cost of a healthcare worker focused outreach intervention strategy versus community organization led outreach to explore contextual factors (individual, family, and community) affecting COVID-19 testing implementation outcomes and scalability.

NCT ID: NCT04766294 Completed - COVID-19 Clinical Trials

Macrophage Activation Markers in COVID-19 Patients

COVID-19
Start date: April 25, 2020
Phase:
Study type: Observational

This study is aiming to find the relation between the severity of COVID-19 in diabetic and obese patients and the high serum levels of matrix metalloproteinase-7 (MMP-7),matrix metalloproteinase-9 (MMP-9), TGF-β and PDGF Macrophage Activation Markers

NCT ID: NCT04765540 Completed - Covid19 Clinical Trials

The Effect of Behaviour Change Interventions on Use of Public Handwashing Stations in Bangladesh

Start date: January 3, 2021
Phase: N/A
Study type: Interventional

As part of the COVID-19 response, BRAC has built 1000 public handwashing stations in several hundred villages in 20 sub-districts of Bangladesh. The investigators investigate the effects of two sets of behavioural interventions on use of the handwashing stations, compared to no additional interventions. The first set comprises passive nudges installed on and around the handwashing station, aimed at attracting people to the station. The second set comprises actively delivered higher-intensity interventions, including free soap offered as an incentive for using the handwashing station and a community board used to display social proof. This set of interventions aims to increase motivation to use the station.

NCT ID: NCT04765475 Completed - COVID-19 Clinical Trials

Protecting Native Families From COVID-19

Start date: March 8, 2021
Phase: N/A
Study type: Interventional

The goal of this study is to increase and hasten testing among those with COVID-19 symptoms and improve adherence to recommended strategies following positive test results in high-risk groups in the White Mountain Apache and Navajo Nation communities.

NCT ID: NCT04765449 Completed - Covid19 Clinical Trials

Transfer of Infection Fighting Immune Cells Generated in the Laboratory to High Risk Patients With COVID-19 Infection

Start date: September 15, 2021
Phase: Phase 1
Study type: Interventional

This clinical trial will study the safety and efficacy of COVID-19-specific T cells when given as treatment to adult patients (age ≥ 18 years) with a COVID-19 infection. This immunologic treatment is aimed at patients, who are at high risk of progression due to their advanced age, or other underlying health conditions. The outcomes of patients receiving the T cells (Arm A) will be compared to patients treated with standard of care (Arm B).